



JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office, T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)
Fax 0091-11-26498341, 26494708, Phone: 0091-11-46181100, 46109900
Email: cs@jagsonpal.com; nandita.singh@jagsonpal.com
CIN No. L74899DL1978PLC009181

July 16, 2022

The Department of Corporate Services- Listing BSE Ltd, Phiroze Jeejeebhoy Towers, Dalal Street Mumbai-400 001 Scrip Code: 507789	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: JAGSNPHARM
--------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015

Ref: Appointment of Managing Director

The Board of Directors at their meeting held today, on the recommendation of the Nomination and Remuneration Committee, have appointed Mr. Manish Gupta as the Managing Director of the Company for a period of 5 (five) years w.e.f. July 16, 2022.

Mr. Manish Gupta is not debarred from holding office of director by virtue of any order by the Securities and Exchange Board of India (“SEBI”) or any other such authority.

Relevant details under the SEBI circular CIR/CFD/CMD/4/2015 dated September 9, 2015, is enclosed herewith.

Further to our earlier intimation dated June 30, 2022 wherein we had informed about resignation of Mr. Rajpal Singh Kochhar, the incumbent Managing Director, we wish to inform you that Mr. Rajpal Singh Kochhar ceased to be the Managing Director /Director with immediate effect consequent to the appointment of Mr. Manish Gupta.

We also attach herewith a press release being issued by the Company on the appointment.

We request you to take the above on record.

Thanking you,

Yours faithfully,

For **Jagsonpal Pharmaceuticals Limited**

Nandita Singh
Company Secretary and Compliance Officer

Appointment of Mr. Manish Gupta as Managing Director

Sr. No	Particulars	Details of Change
1.	Reason for change. viz. appointment, resignation, removal, death or appointment otherwise	Appointment Mr. Manish Gupta (DIN: 06805265) as the Managing Director
2.	Date of appointment	July 16, 2022
3.	Term of appointment	For a period of 5 (five years) from date of appointment, subject to approval of shareholders.
4.	Brief profile (in case of appointment)	<p>Manish has a well-established track record of successfully leading and managing businesses across the globe. His last stint was with SeQuent Scientific Limited (SeQuent) as the CEO and Managing Director for 8 years. Previously, he has been the CEO – Pharma Business for Strides Pharma Science. Prior to that, he was associated with Wockhardt in various capacities with his last role being as the Managing Director of Pinewood Healthcare, Ireland and CEO of Radiant Research, a CRO in USA.</p> <p>Manish led SeQuent since 2014 and played a major role in transforming the Company from a small India-focused business to a global organization with operations in India, Turkey, Brazil and the EU, emerging as India's largest and 'top 20' global animal health company. He undertook a series of structural moves including inorganic initiatives with emphasis on consolidating market presence, entering new markets, and strengthening customer-centricity.</p>
5.	Disclosure of relationships between directors (in case of appointment of Director)	None



Jagsonpal Pharmaceuticals appoints Mr. Manish Gupta as the Managing Director

New Delhi, July 16, 2022: Jagsonpal Pharmaceuticals Limited (BSE: 507789), NSE: JAGSNPHARM) today announced the appointment of Mr. Manish Gupta as the Managing Director of the Company.

Manish has a well-established track record of successfully leading and managing businesses across the globe. His last stint was with SeQuent Scientific Limited (SeQuent) as the CEO and Managing Director for 8 years. Previously, he has been the CEO – Pharma Business for Strides Pharma Science. Earlier, he was associated with Wockhardt in various capacities, his last role being the Managing Director of Pinewood Healthcare, Ireland and CEO of Radiant Research, a CRO in USA.

Manish led SeQuent since 2014 and played a major role in transforming the Company from a small India-focused business to a global organization with operations in India, Turkey, Brazil and the EU, emerging as India's largest and 'Top 20' global animal health company. He undertook a series of structural moves including inorganic initiatives with emphasis on consolidating market presence, entering new markets and strengthening customer-centricity.

Mr. Rajpal Singh Kochhar, Founder and the incumbent Managing Director who led Jagsonpal since inception has stepped down. Mr. Rajpal Singh Kochhar and family will continue to be a part of the Promoter Group of the Company.

Commenting on the development, Mr. Rajpal Singh Kochhar stated "While it's a difficult decision and moment to pass on the mantle of a business which we built from scratch over decades, I am happy that we have found the right partners to take the Company to the next level with a strong focus on growth and profitability. I take this opportunity to thank each and every one at Jagsonpal and in particular the Directors for their commitment. I wish Manish the very best and looking forward to see Jagsonpal delivering greater value to all stakeholders."

On the new role, Manish stated that "I am excited to take up the mantle to lead Jagsonpal, which I believe has a great business model and talented team. I look forward to work closely with the new Board to build on the great foundation laid by Mr. Rajpal Singh Kochhar, with a focus on growth and profitability."

ABOUT JAGSONPAL PHARMACEUTICALS LIMITED

Jagsonpal Pharmaceuticals Limited is a Delhi based pharmaceutical company. Founded in 1964, the Company has a proven track record of 58 years catering to the Indian pharmaceutical market.

The Company has a robust portfolio of drugs focusing on Gynecology and Orthopedic segments. Over the years, the Company has successfully built multiple brands which today hold market leading position in respective segments. It has created a niche for itself in these valueaccretive segments which resulted in mid-teens CAGR in revenues over the last four years reaching ₹ 2,294 Millions in FY22. It has extensive pan-India presence through its strong sales team of 800+ individuals.

Infinity Holdings recently acquired majority stake in the company and is a joint promoter of the company. The company is listed on the National Stock Exchange Limited (NSE) and Bombay Stock Exchange Limited (BSE).

For more on the Company please visit. www.jagsonpal.com.

Mr. S.V. Subha Rao
Chief Financial Officer

Contact: svrao@jagsonpal.com; 01146181100

Jagsonpal Pharmaceuticals Limited
CIN: L74899DL1978PLC009181
T-210 J, Shahpur Jat, New Delhi – 110049